西尼罗河病毒疫苗方法综述。
A review of vaccine approaches for West Nile virus.
机构信息
Division of Biotechnology and Molecular Medicine, Louisiana State University School of Veterinary Medicine, Skip Bertman Drive, Baton Rouge, LA 70803, USA.
出版信息
Int J Environ Res Public Health. 2013 Sep 10;10(9):4200-23. doi: 10.3390/ijerph10094200.
The West Nile virus (WNC) first appeared in North America in 1999. The North American lineages of WNV were characterized by the presence of neuroinvasive and neurovirulent strains causing disease and death in humans, birds and horses. The 2012 WNV season in the United States saw a massive spike in the number of neuroinvasive cases and deaths similar to what was seen in the 2002-2003 season, according to the West Nile virus disease cases and deaths reported to the CDC by year and clinical presentation, 1999-2012, by ArboNET (Arboviral Diseases Branch, Centers for Disease Control and Prevention). In addition, the establishment and recent spread of lineage II WNV virus strains into Western Europe and the presence of neurovirulent and neuroinvasive strains among them is a cause of major concern. This review discusses the advances in the development of vaccines and biologicals to combat human and veterinary West Nile disease.
西尼罗河病毒（WNV）于 1999 年首次出现在北美洲。WNV 的北美观测株系具有神经侵袭性和神经毒性，可导致人类、鸟类和马匹患病和死亡。根据疾病控制与预防中心（CDC）通过 ArboNET（虫媒病毒疾病科）按年份和临床表现报告的 1999 年至 2012 年西尼罗河病毒疾病病例和死亡数据，与 2002-2003 年季节类似，2012 年美国的西尼罗河病毒季节出现了神经侵袭性病例和死亡数量的大幅增加。此外，谱系 II WNV 病毒株在西欧的建立和最近的传播，以及其中存在的神经毒性和神经侵袭性株系，是一个主要关注的问题。本文综述了针对人类和兽医西尼罗河疾病的疫苗和生物制剂的研发进展。
Zotero 插件